Selective pressure-regulated retroinfusion of coronary veins as an alternative access of ischemic myocardium: implications for myocardial protection, myocardial gene transfer and angiogenesis.
There is renewed interest in the coronary venous system as an alternative access to ischemic myocardium. Selective pressure-regulated retroinfusion is a catheter-based approach which has been shown to increase the efficacy of retrograde oxygen delivery and drugs in experimental and clinical studies. Selective pressure-regulated retroinfusion may also target retrograde delivery of angiogenic growth factors and gene vectors to ischemic myocardium.
Boekstegers
P
P
Klinikum Grosshadern, Ludwig-Maximilians-Universität of Munich, 81366 Munich, Germany. boekstegers@med1.med.uni-muenchen.de
von Degenfeld
G
G
Giehrl
W
W
Kupatt
C
C
Franz
W
W
Steinbeck
G
G
D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D000818:Animals; D006328:Cardiac Catheterization; D003326:Coronary Circulation; D003331:Coronary Vessels; D004562:Electrocardiography; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage; D015870:Gene Expression; D018014:Gene Transfer Techniques; D017930:Genes, Reporter / Q000235:genetics; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods*; D009203:Myocardial Infarction / Q000628:therapy; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000628:therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011312:Pressure; D012770:Shock, Cardiogenic / Q000628:therapy; D013552:Swine; D013997:Time Factors
D043925:Angiogenesis Inducing Agents; D004364:Pharmaceutical Preparations; D016222:Fibroblast Growth Factor 2